Scientific Advisory Group · New York City · Est. 1998

Early-Stage Biotech
Asset Sourcing & Evaluation

US-based scientific advisory group specializing in global early-stage asset sourcing and evaluation.

Long-term, exclusive partner to a Japanese-headquartered mid-size biopharmaceutical company and its World-Wide subsidiaries.

Contact Us Our Approach
25+
Years of experience
9,400+
Opportunities sourced

Founded in 1998 in New York City, Trillium Medical Ventures has been a trusted partner in bioscience technology assessment for over 25 years. We evaluate life science technologies to identify exceptional drug discovery and product development opportunities for our partners.

We cover the full drug development cycle, from early-stage research to global clinical programs. Our pharmaceutically trained team brings deep, hands-on expertise in biopharmaceutical science and rigorous scientific evaluation, providing partners with the clarity they need to move forward with confidence.

Trillium Medical Ventures · New York, NY · Founded 1998

Our Services

End-to-End Search & Evaluation Services

From continuous asset sourcing to deep scientific diligence, TMV provides the competitive intelligence
needed to make confident partnership and investment decisions.

Technology Search & Evaluation
Continuous sourcing and rigorous scientific evaluation of innovative early-stage assets, translational animal models, and R&D-enabling cutting-edge platform technologies.
In-Licensing Opportunities
Identification and BD contacts for clinical and preclinical assets for the Japanese pharmaceutical market.
KOL Interviews
Expert interviews with leading academic and industry scientists globally, providing independent and rigorous perspective on emerging science.
Competitive Intelligence
In-depth tracking of companies, compounds, clinical trials, and market dynamics to keep your strategy ahead of the curve.
Scientific & Partnering Meetings
Active presence at BIO International, BIO Europe, ChinaBio, JPM Week, LSX, and key scientific conferences, ensuring early access to emerging science and off-market opportunities.
Special Project Requests
Custom reports and follow-up diligence responding directly to partner R&D and Business Development team needs.

Scientific Coverage

Therapeutic Focus Areas

Our scientific coverage spans three decades of evolving therapeutic priorities,
from chronic disease to Rare Disease/ precision medicine and cutting-edge drug discovery platforms.

1998 – 2023
Chronic Diseases
  • Cardiometabolic: T2D, Dyslipidemia, Obesity, NASH/Liver Fibrosis, Heart Failure (HFrEF, HFpEF, HCM), PAD, PAH
  • Diabetic Complications: Retinopathy, Macular Edema, Nephropathy, Peripheral Neuropathic Pain
  • Neurodegeneration: Alzheimer's, Parkinson's, ALS, Schizophrenia
  • Psychiatric: Depression
  • Renal: CKD
  • Dermatology: Atopic Dermatitis, Psoriasis, Alopecia Areata, Chronic Spontaneous Urticaria
  • Allergen Immunotherapy & Allergic Diseases: Allergic Rhinitis, Asthma, Chronic Rhinosinusitis
  • ENT Diseases: Hearing Impairments, Balance Disorders
  • Inflammation & Autoimmunity: MS, RA, IBD, SLE, Scleroderma
  • Infectious Diseases: HIV, HBV, HCV, EBV
  • Musculoskeletal: Sarcopenia, Cachexia, Osteoporosis
2023 – Present
Rare and Genetic Diseases & Precision Medicine
  • Cardiovascular: Hypertrophic, Restrictive & Dilated Cardiomyopathy; Genetic CV & Hematologic Diseases
  • Renal: ADPKD, Genetic Cystic Kidney Diseases, Genetic Glomerular Diseases (FSGS, Alport Syndrome, Nephrotic Syndrome)
  • Neuromuscular: SMA, Duchenne/Becker MD, FSHD, Myotonic Dystrophy, CMT, Friedreich's Ataxia, GNE Myopathy
  • CNS: Leukodystrophy, Lysosomal & Mitochondrial Diseases; Precision Medicine for Alzheimer's, Parkinson's, ALS, Schizophrenia
  • Immune-Mediated & Monogenic Immune Disorders
  • Ophthalmology & Dermatology
  • Other Early-Stage & Clinical Rare Diseases
  • Animal and Organoid disease models
1998 – Present
Drug Discovery Enabling Technologies
  • Target Identification: Target Deconvolution, mAb design and production
  • Hit & Lead Generation: HTS, Fragment screening, Biophysical techniques, Phenotypic screening, DNA-encoded Libraries, Small-molecule library design
  • CNS Translational Research: Biomarkers, Non-clinical assays
  • RNA & Epigenetics: Translation regulation, DNA/RNA methylation, ER stress, Autophagy, Epigenetic modulation, Exosome transmission
  • Targeted Protein Degradation: PROTACs, Molecular Glues, E3 ligand discovery
  • Computational & AI: Protein folding, AI/ML, Quantum Computing, Omics datasets
  • Chemical Biology: SBDD, FBDD, Macrocycles, Allosteric Inhibitors, PPI, Chaperones, Cryptic Pockets, RNA-Targeted Small Molecules

Proven Results

A 25-Year Track Record of Consistent Delivery

From target discovery through late-stage clinical, with all records stored in a proprietary, relational database of curated opportunities.

9,400+
Total opportunities
introduced to partners
∼200
Strategic Research Opportunities
identified per year
>95%
Opportunities designated as
"Valuable/Impressive" by partner

Partnership Opportunity

Are You the Right Fit?

We are actively seeking early-stage R&D collaborations with industry or academic groups on innovative targets, drug candidates, and enabling technologies on behalf of our global pharmaceutical partner.

  • Early-Stage Biotechs
    Preclinical through Phase 2 assets in any of our therapeutic focus areas
  • Novel Mechanisms
    First-in-class targets or differentiated approaches to validated biology
  • Technology Platforms
    Enabling drug discovery technologies including AI/ML, RNA targeting, targeted protein degradation
  • Open to Partnership
    Interested in collaboration, alliance, or in-licensing discussions with established Biotechs/Pharmas

Our People

Our team combines deep scientific training with decades of industry experience across
pharma, biotech, and academia.

Lynne H. Parker
Lynne H. Parker, PhD
Founder & Managing Partner
Biological Chemistry
Lynne has had a long career in drug discovery, preclinical development, business development and venture investing in the pharmaceutical industry (Roche, Sandoz and Schering, AG/Berlex Laboratories). She led strategic business development and venture capital groups at Berlex/Schering AG, including Director of the Office of Technology and President of Schering Berlin Venture Corporation. She had responsibility for finding, evaluating, acquiring and commercializing cutting-edge technologies, starting new companies and evaluating companies as acquisition candidates. Dr. Parker founded Trillium Medical Ventures, LLC in November of 1998.
Steven C. Bailey
Steven C. Bailey, PhD
Founder & General Partner
Pharmacology
Steven conducted drug discovery, preclinical development and business development at Hoechst and Schering AG/Berlex Laboratories across a number of therapeutics areas. At Hoechst, he led preclinical teams for drug discovery and toxicology. At the CRO, M. Hurley and Associates, he audited and compiled pharmacology and toxicology reports and authored Efficacy and Safety sections for 4 approved New Drug Applications. Dr. Bailey has also helped manage the investments of Schering Berlin Venture Corporation, a venture capital fund investing in health care sector, where he was responsible for Search and Evaluation and managing due diligence of licensing and investment opportunities. Co-founded Trillium Medical Ventures in 1998.
Guadalupe Cipres
Guadalupe Cipres, PhD
Partner
Molecular Biology & Biochemistry
Guadalupe brings extensive experience in academic biomedical research and technology development, with expertise in gene expression regulation and therapeutic DNA delivery technologies. As Associate Director at the New York Biotechnology Association, she collaborated with leading New York research institutions to identify early-stage innovations and foster strategic partnerships with industry. She also served as an advisor to the New York City Mayor's Biotechnology Task Force, contributing insights on industry needs and growth. She joined Trillium Medical Ventures in 2000.
Natalia Frias-Staheli
Natalia Frias-Staheli, PhD
Principal
Biochemistry, Molecular Virology & Immunology
Natalia is a biochemist and virologist with expertise in virus–host interactions and viral disease mechanisms. Her academic research contributed to the molecular characterization of highly pathogenic RNA viruses, the development of animal models, and translational studies in virology. In industry, she led bioanalytical and pharmacology IND-enabling studies for a monoclonal antibody program at ContraFect Corp., overseeing assay development, CRO management, and regulatory compliance. She also supported early-stage assay development for glioblastoma therapy at Sapience Therapeutics. She joined Trillium Medical Ventures in 2017.
Mayra Jimenez
Mayra Jimenez, BSc
Data & Office Management
Biology
Mayra is a Data Scientific Manager with seven years of experience. A graduate of Queens College, City University of New York, with a B.A. in Biology, she manages the Access database of research opportunities and provides administrative support. She joined Trillium Medical Ventures in 2019.

Get In Touch

Ready to Explore
a Partnership?

If your company is working in one of our therapeutic areas and is open to partnering with a major pharmaceutical organization, we'd love to hear from you.

Thank you for reaching out. A member of the TMV team will review your submission and be in touch shortly.
Address
307 Seventh Avenue
New York, NY 10001
LinkedIn
Trillium Medical Ventures